Correlation Between IFNγ+ and CTLA-4+ Tumor Infiltrating Lymphocytes In Luminal And Non-Luminal Breast Carcinoma

Irene Lingkan Parengkuan, Sjahjenny Mustokoweni, Nila Kurniasari

Abstract

ABSTRACT

The role of tumor infiltrating lymphocytes (TIL) in breast carcinoma depends on the molecular subtype, especially the expression of the estrogen receptor. A greater mutation load in the non-luminal subtype leads to continuous activation of the immune system resulting in exhausted T lymphocytes. Observational research with a cross-sectional approach was conducted on 40 formalin fixed paraffin-embedded tissue from breast carcinoma at the Anatomical Pathology Laboratory of Dr. Soetomo General Hospital Surabaya during January 2017 -  December 2018. Samples were divided into two groups based on their status of ER expression. The parameter was a positive percentage of TIL immunoreactivity against IFNγ and CTLA-4 antibodies. Percentage of IFNγ+ TIL is higher in the luminal subtype (p =0.001), whereas the percentage of CTLA-4+ TIL is higher in the non-luminal (p =0.001). These expressions were significantly correlated with the molecular subtype of breast carcinoma (p=0.001). A significant correlation between IFNγ+ and CTLA-4+ TIL were found (rs=-0.350, p=0.027). Exhausted T lymphocytes express some inhibitor molecules such as CTLA-4. CTLA-4 (Cytotoxic T-Cell Lymphocyte Associated Protein-4) suppresses immune system function including the activity of IFN-γ as an important molecule in anti-tumor immunity and forms an immunosuppressive and pro-tumor microenvironment. Different level of expressions of IFNγ+ (p=0.001) and CTLA-4 + (p=0.001) TIL were proven to be related to the molecular subtype of breast carcinoma (rs=-0.683, p=0.001; rs=0,501, p=0.001, respectively). The negative correlation between IFNγ+ and CTLA-4+ TIL shows the role of CTLA-4 as an inhibitory molecule to the immune system (rs=-0.350, p=0.027).

Keywords : tumour infiltrating lymphocytes, IFNγ, CTLA-4, breast carcinoma,  luminal molecular subtype

Correspondence to: lingkan.parengkuan@gmail.com

 

ABSTRAK

Peran tumour infiltrating lymphocytes (TIL) pada karsinoma payudara berhubungan erat dengan subtipe molekuler, terutama ada atau tidaknya ekspresi reseptor estrogen. Beban mutasi yang besar pada subtipe non-luminal menyebabkan pengaktifan sistem imun terjadi terus menerus dengan hasil akhir terbentuknya subset limfosit T yang kelelahan. Penelitian observasional analitik dengan pendekatan potong lintang ini menggunakan sampel 40 blok parafin dari penderita karsinoma payudara di Laboratorium Patologi Anatomi RSUD Dr. Soetomo Surabaya periode 1 Januari 2017 – 31 Desember 2018 yang dibagi menjadi 2 kelompok berdasarkan ada atau tidaknya ekspresi reseptor estrogen. Parameter penilaian adalah jumlah persentase TIL area tumor invasif yang terpulas positif dengan antibodi IFNγ dan CTLA-4. Ekspresi IFNγ+ TIL didapatkan lebih tinggi pada subtipe luminal (p=0,001), sedangkan ekspresi CTLA-4+ TIL didapatkan lebih tinggi pada subtipe non-luminal (p=0,001). Analisis statistik menunjukkan adanya korelasi signifikan antara ekspresi IFNγ+ TIL dengan CTLA-4+ TIL (rs=-0,350, p=0,027). Salah satu sifat dari sel limfosit T kelelahan adalah mengekspresikan molekul inhibitor sistem imun antara lain CTLA-4 (Cytotoxic T-Cell Lymphocyte Associated Protein-4). CTLA-4 akan menekan fungsi sistem imun dan berdampak pada penurunan aktivitas IFN-γ yang merupakan salah satu molekul penting dalam imunitas anti-tumor sehingga terbentuklah lingkungan mikro yang imunosupresif dan pro-tumor. Hasil penelitian menunjukkan adanya perbedaan ekspresi IFNγ+ TIL (p=0,001) dan CTLA-4+ TIL (p=0,001) pada kedua kelompok yang secara bermakna berhubungan dengan subtipe molekuler karsinoma payudara (secara berurutan mendapatkan nilai (rs=-0,683, p=0,001 dan rs=0,501, p=0,001). Korelasi negatif antara IFNγ+ TIL dengan CTLA-4+ TIL menunjukkan adanya peran CTLA-4 sebagai molekul inhibisi terhadap sistem imun (rs=-0,350, p=0,027).

Kata kunci                  : tumour infiltrating lymphocytes, IFNγ, CTLA-4, karsinoma payudara, subtipe molekuler luminal

Korespondensi            :lingkan.parengkuan@gmail.com

Keywords

research article

Full Text:

PDF

References

Allison, K. H. and Sam, C. M. E. (2012) ‘Molecular Pathology of Breast Cancer What a Pathologist Needs to Know’, Am J Clin Pathol, 138, pp. 770–780. doi: 10.1309/AJCPIV9IQ1MRQMOO.

Ayu, G. Hendrati, L. (2015) ‘Analisis risiko kanker payudara berdasar riwayat pemakaian kontrasepsi hormonal dan usia’, Jurnal Berkala Epidemiologi, 3(1), pp. 12–23.

Bray, F., Ferlay, J. Soerjomataram, I., Siegel, R. Torre, L. Jemal, A. (2018) ‘Global Cancer Statistics 2018 : GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries’, Ca Cancer J Clin, 68, pp. 394–424. doi: 10.3322/caac.21492.

Catakovic, K. Klieser, E., Neureiter, D., Geisberger, R. (2017) ‘T cell exhaustion : from pathophysiological basics to tumor immunotherapy’, Cell Communication and Signaling. Cell Communication and Signaling, 15(1), pp. 1–16. doi: 10.1186/s12964-016-0160-z.

Dai, X. Xiang, L., Li, T., Bai, Z. (2016) ‘Cancer Hallmarks , Biomarkers and Breast Cancer Molecular Subtypes’, Journal of Cancer, 7(10), pp. 1281–1294. doi: 10.7150/jca.13141.

Grosso, J. F. and Jure-kunkel, M. N. (2013) ‘CTLA-4 blockade in tumor models : an overview of preclinical and translational research’, Cancer Immunity Review, 13(January), pp. 1–14.

Hammerl, D. Smid, M. Timmermans, A. M. Sleijfer, S. Martens, J. W. M. Debets, R. (2017) ‘Breast cancer genomics and immuno-oncological markers to guide immune therapies’, Seminars in Cancer Biology. Elsevier, (October), pp. 1–11. doi: 10.1016/j.semcancer.2017.11.003.

Karachaliou, N., Gonzalez-cao, M., Crespo, G., Drozdowskyj, A., Aldeguer, E., Gimenez-capitan, A. (2018) ‘Interferon gamma , an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients’, Therapeutic Advances in Medical Oncology, 10, pp. 1–23. doi: 10.1177/https.

Kotoula, V. Chatzopoulos, K., Lakis, S., Alexopoulou, Z., Timotheadou, E., Zagouri, F., Pentheroudakis, G., Gogas, H., Galani, E., Efstratiou, I., Zaramboukas, T., Koutras, A., Aravantinos, G., Samantas, E., Psyrri, A., Kourea, H., Bobos, M., Papakostas, P., Kosmidis, P., Pectasides, D., Fountzilas, G. (2015) ‘Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer : a pooled analysis of four prospective adjuvant trials’, Oncotarget, 7(4).

Law, A. Lim, E. Ormandy, C. J. dan Gallego-Ortega, D. (2017) ‘The innate and adaptive infiltrating immune systems as targets for breast cancer immunotherapy’, Endocr Relat Cancer, 24(4), pp. R123–R144.

Makki, J. (2015) ‘Diversity of Breast Carcinoma : Histological Subtypes and Clinical Relevance’, pp. 23–31. doi: 10.4137/CPath.S31563.TYPE.

Mao, H. Zhang, L., Yang, Y., Zuo, W., Bi, Y., Gao, W., Deng, B., Sun, J., Shao, Q., Qu, X. (2010) ‘New Insights of CTLA-4 into Its Biological Function in Breast Cancer’, Current Cancer Drug Target, 10, pp. 728–736.

Mo, X., Zhang, H., Preston, S., Martin, K., Zhou, B., Vadalia, N., Ana, M., Soboloff, J., Tempera, I., Zaidi, M R. (2017) ‘Interferon gamma signaling in melanocytes and melanoma cells regulates expression of CTLA - 4’, American Association for Cancer Journal. doi: 10.1158/0008-5472.CAN-17-1615.

Nizuwan, A., Nurdianah, H. F. and Musa, M. Y. (2016) ‘INTERRELATIONSHIP OF CLINICOPATHOLOGICAL FEATURES OF BREAST CANCER AMONG DIFFERENT ETHNIC GROUPS’, Jurnal Teknologi (Sciences and Engineering), 3(2), pp. 51–56.

Pandiyan, P., Hegel, J. K. E., Kueger, M., Quandt, D., Brunner-weinzierl, M. C. (2007) ‘High IFN- γ Production of Individual CD8 T Lymphocytes Is Controlled by CD152 (CTLA-4)’, The Journal of Immunology, 152(178), pp. 2132–2140. doi: 10.4049/jimmunol.178.4.2132.

Ravelli, A. Roviello, G., Cretella, D., Cavazzoni, A., Biondi, A., Cappelletti, M. R., Zanotti, L., Ferrero, G., Ungari, M., Zanconati, F., Bottini, A., Alfieri, R., Petronini, P. G., Generali, D. (2017) ‘Tumor-infiltrating lymphocytes and breast cancer : Beyond the prognostic and predictive utility’, Tumor Biology. doi: 10.1177/1010428317695023.

Rowshanravan, B. Halliday, N. dan Sansom, D. M. (2017) ‘CTLA-4 : a moving target in immunotherapy’, Blood, 131(1), pp. 58–67. doi: 10.1182/blood-2017-06-741033.

Rudd, C. E. (2012) ‘CTLA-4 co-receptor impacts on the function of Treg and CD8 + T- cell subsets’, Eur J Immunol., 39(3), pp. 687–690. doi: 10.1002/eji.200939261.CTLA-4.

Si, W., Li, Y., Han, Y., Zhan, F., Wang, Y., Linghu, R. X., Zhang, X., Yang, J. (2015) ‘Epidemiological and Clinicopathological Trends of Breast Cancer in Chinese Patients During 1993 to 2013. A Retrospective Study’, Medicine, 94(26), pp. 1–7. doi: 10.1097/MD.0000000000000820.

Sinn, H. and Kreipe, H. (2013) ‘A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition’, Breast Care, 8, pp. 149–154. doi: 10.1159/000350774.

Spurrell, E. L. and Lockley, M. (2014) ‘Adaptive immunity in cancer immunology and therapeutics’, e-cancer medical science, 8(441), pp. 1–10. doi: 10.3332/ecancer.2014.441.

Staton, S. E., Adams, S. and Disis, M. L. (2016) ‘Variation in the Incidence and Magnitude of Tumor-Infiltrating Lymphocytes in Breast Cancer Subtypes. A Systematic Review’, JAMA Oncol., 8050. doi: 10.1001/jamaoncol.2016.1061.

Staton, S. E. and Disis, M. L. (2016) ‘Clinical significance of tumor-infiltrating lymphocytes in breast cancer’, Journal for ImmunoTherapy of Cancer. Journal for ImmunoTherapy of Cancer, pp. 1–7. doi: 10.1186/s40425-016-0165-6.

Varn, F. S. Mullins, D. W. Arias-Pulido, H. Fiering, S. dan Cheng, C. (2016) ‘Adaptive immunity programmes in breast cancer’, Immunology, 150, pp. 25–34. doi: 10.1111/imm.12664.

Wherry, E. J. and Kurachi, M. (2016) ‘Molecular and cellular insights into T cell exhaustion’, Nat Rev Immunol, 15(8), pp. 486–499. doi: 10.1038/nri3862.

Widodo, I. Dwianingsih, E. K., Triningsih, E., Utoro, T. (2014) ‘Clinicopathological Features of Indonesian Breast Cancers with Different Molecular Subtypes’, 15(15), pp. 6109–6113.

Yu, L. Tang, J. Zhang, C. M. Zeng, W. J. Yan, H. Li, M. P.dan Chen, X. P. (2017) ‘New Immunotherapy Strategies in Breast Cancer’, International Journal of Environmental Research and Public Heath, 14(68), pp. 1–18. doi: 10.3390/ijerph14010068.

Zhao, Y. Yang, W. Huang, Y. Cuia, R. Lie, X. dan Lia, B. (2018) ‘Evolving Roles for Targeting CTLA-4 in Cancer Immunotherapy’, Cell Physiol Biochem, (47), pp. 721–734. doi: 10.1159/000490025.


DOI: http://dx.doi.org/10.30651/jqm.v3i2.2778